Related Experiment Videos
Digitalis toxicity in infants and children.
Pediatric Cardiology
|April 1, 1984
Summary
Cardiac glycoside drug levels are hard to manage, with small differences between therapeutic and toxic doses. Radioimmunoassays have improved understanding, but digitalis toxicity remains a concern in pediatric patients.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Clinical Toxicology
Background:
- Cardiac glycosides possess a narrow therapeutic index, making precise dosing critical.
- Recent advancements in radioimmunoassays have enhanced the understanding of cardiac glycoside pharmacokinetics and clinical applications.
- Digitalis toxicity continues to be a significant clinical issue, particularly in pediatric populations.
Purpose of the Study:
- To review the pharmacokinetic properties and clinical utility of cardiac glycosides.
- To highlight the persistent challenge of digitalis toxicity in infants and children despite improved measurement techniques.
Main Methods:
- Review of pharmacokinetic data derived from radioimmunoassay measurements.
- Analysis of clinical outcomes and toxicity reports in pediatric patients.
Main Results:
- Radioimmunoassays provide accurate quantification of cardiac glycoside levels, aiding in therapeutic drug monitoring.
- Improved pharmacokinetic understanding has refined clinical use, yet toxicity remains prevalent in pediatric cases.
Conclusions:
- Accurate measurement of cardiac glycosides is essential due to their narrow therapeutic range.
- Pediatric patients remain at high risk for digitalis toxicity, necessitating careful monitoring and management strategies.